
==== Front
Clin Exp Metastasis
Clin Exp Metastasis
Clinical & Experimental Metastasis
0262-0898
1573-7276
Springer Netherlands Dordrecht

38281256
10267
10.1007/s10585-024-10267-5
Review
Clinical applications of circulating tumor cells in patients with solid tumors
Smit Daniel J. 12
Schneegans Svenja 1
Pantel Klaus pantel@uke.de

12
1 https://ror.org/01zgy1s35 grid.13648.38 0000 0001 2180 3484 Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
2 https://ror.org/01zgy1s35 grid.13648.38 0000 0001 2180 3484 Fleur Hiege Center for Skin Cancer Research, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
28 1 2024
28 1 2024
2024
41 4 403411
22 8 2023
11 1 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The concept of liquid biopsy analysis has been established more than a decade ago. Since the establishment of the term, tremendous advances have been achieved and plenty of methods as well as analytes have been investigated in basic research as well in clinical trials. Liquid biopsy refers to a body fluid-based biopsy that is minimal-invasive, and most importantly, allows dense monitoring of tumor responses by sequential blood sampling. Blood is the most important analyte for liquid biopsy analyses, providing an easily accessible source for a plethora of cells, cell-derived products, free nucleic acids, proteins as well as vesicles. More than 12,000 publications are listed in PubMed as of today including the term liquid biopsy. In this manuscript, we critically review the current implications of liquid biopsy, with special focus on circulating tumor cells, and describe the hurdles that need to be addressed before liquid biopsy can be implemented in clinical standard of care guidelines.

Keywords

Liquid biopsy
Circulating tumor cells
Clinical application
Precision medicine
Universitätsklinikum Hamburg-Eppendorf (UKE) (5411)Open Access funding enabled and organized by Projekt DEAL.

issue-copyright-statement© Springer Nature B.V. 2024
==== Body
pmcIntroduction

Despite tremendous efforts in clinical and basic cancer research, metastasis remains a key driver of cancer-associated mortality [1]. Therefore, early detection of both localized as well as metastasized cancers is of utmost importance for the survival of these patients. During metastasis, cancer cells detach from the primary tumor, infiltrate the local tissue, intravasate into blood vessels and ultimately invade into distant organs, where they need to be able to proliferate to form new metastases [2]. To achieve this, the tumor cells need to switch from an immotile to a more migratory state, a process called epithelial–mesenchymal transition (EMT), during which epithelial molecules are downregulated while simultaneously mesenchymal proteins are upregulated [3]. Moreover, EMT leads to the activation of several transcription factors such as Slug, Snail, Twist, and ZEB1/2 [3], ultimately resulting in alterations in signalling pathways changing polarity, cell-cell contacts and extracellular matrix composition, therefore enhancing invasive properties [4]. Once the detached cells arrive at the metastatic site, these traits need to be reversed through MET (mesenchymal to epithelial transition) to facilitate re-attachment, proliferation, and metastatic outgrowth [4].

Tumor cells that have undergone this process are called disseminated tumor cells (DTCs) and are frequently found in the bone marrow or lymph nodes. Other major, clinically relevant sites of metastases include the liver, the lung, the bone and the brain but are dependent on the anatomically determined lymphatic and venous drainage, the molecular characteristics of the primary tumor as well as the corresponding microenvironments of the secondary organs [5]. The presence of DTCs in the bone marrow negatively correlates with the survival of patients with various cancer entities [6, 7]. DTCs are tumor cells that have left the lymphatic or blood vessels and subsequently settled at lymph nodes or distant sites (e.g., bone marrow). DTCs occur at very low concentrations (e.g., 1 per 1 million bone marrow cells and highly sensitive methods are required for their detection (e.g., immunocytochemistry with keratin antibodies). Considering the total mass of bone marrow, it can be estimated that an early stage breast cancer patient at initial diagnosis can harbor hundred thousands of DTCs in the bone marrow and approximately 50% of these patients can control this tumor load over 10 years [8]. Understanding the mechanisms of this remarkable control might open new avenues for therapeutic interception aimed to block the development into full blown and incurable metastasis. To date, we know that DTCs can adapt to different microenvironments, reside in a non-proliferate (Ki67-negative) state, express oncogenes such as HER2, develop resistance against systemic anti-cancer treatment as well as acquire cancer stem cell (CSC)-like traits [9–11]. Bone marrow aspiration is an invasive procedure routinely used in patients with haematological malignancies but not in patients with solid tumors. Despite the promising clinical research studies on DTCs, the emerging interest in blood analyses (e.g., CTCs and ctDNA) has lowered the interest to implement DTC analyses into clinical protocols. However, we are confident that DTC analyses would add an important information that might be not obtained by minimally invasive blood tests which provide only a snap shot. Tumor cells that can be detected in the circulation are called circulating tumor cells (CTCs), however, as opposed to DTCs, they have not settled yet in a distant organ. For survival, these cells that have detached from the primary tumor or secondary metastatic sites circulate in the blood stream and have to withstand extreme conditions including high pressure within the vessels as well as evade immune surveillance mechanisms and adapt to a new microenvironment [12]. Unlike tissue biopsies, sampling of CTCs not only allows a comprehensive assessment of the state of the disease but also represents a non-invasive tool for sequential and real-time monitoring of tumor burden in cancer patients. Blood as a liquid biopsy source provides a convenient, easily accessible, and fast way of sampling and enables the investigation of different analytes apart from CTCs such as circulating nucleic acids (ctDNA, miRNAs), extracellular vesicles (EVs) and platelets. All analytes can provide complementary information on the (epi-)genomic, transcriptomic, and proteomic level which are highly valuable for the molecular characterization of the tumor burden in an individual cancer patient [13].

Analysis of CTCs to understand the biology of metastasis

While in early-stage cancer the primary tumor serves as the main source for CTCs, ctDNA and EVs (and in later stages also the lymph nodes), in more advanced cancers, metastases are mainly responsible for releasing CTCs and other cancer cell derived products into the circulation [14]. Using CTCs as liquid biomarkers presents a challenge, not only because of their short half-life of approximately 1-2.4 h [15] but also because especially in early stages the number of CTCs shed into the peripheral blood circulation is low compared to the vast background of blood cells. It is estimated that one CTC can be found per approximately 106-108 leukocytes [16], however, this number also strongly varies between the different tumor entities and disease stages. For analysis of CTCs, enrichment is thus indispensable and can be performed using a variety of devices and techniques.

By making use of the physical and mechanical properties of CTCs and leukocytes, separation of these two cell populations can for example be achieved through differences in size, deformability, density, or electric charges using devices, with new technologies being constantly developed [17].

Biological properties such as expression of specific cell surface markers on the other hand, are furthermore necessary to ultimately distinguish between CTCs and leukocytes and thus for their identification and enumeration and therefore prognostic and diagnostic value.

The most prominent CTC marker EpCAM (epithelial cell adhesion molecule) is currently being utilized in the only FDA-approved CTC detection platform to date, the CellSearch system, in which CTCs are enriched through adhesion to anti-EpCAM-conjugated magnetic beads. However, during metastasis, cells detaching from the tumor sites and undergoing EMT, often show a significant downregulation of epithelial proteins such as EpCAM [18]. Negative depletion of immune cells including anti-CD45 conjugates for leucocyte depletion is therefore another option of CTC enrichment. The epithelial ImmunoSPOT (EPISPOT) assays can be used to detect cancer-specific proteins secreted by viable CTCs such as cytokeratins, having proven to show prognostic value in breast, colon, prostate, and head and neck tumors and melanoma [17, 19]. Moreover, the EPIDROP assay is currently being developed for detection of CTCs in microdroplets at the single cell level [20].

Through these various techniques, an enrichment of CTCs by several log scales can be achieved which is necessary for effective subsequent molecular characterization on a single cell level [20] (Fig. 1).

Fig. 1 Overview of analytes in blood-based liquid biopsy analysis and CTC detection. Body fluids represent a rich source of cells as well as acellular products that can be assessed by liquid biopsy. Although liquid biopsy can be applied to all body fluids, the blood is most popular fluid within the field. Blood is composed of a cellular as well as acellular fraction. Within the soluble fraction, several liquid biopsy analytes including cell-free RNA, cell-free DNA, extracellular vesicles, (micro-)proteins as well as metabolites can be isolated. Circulating tumor cells (CTCs), if present, are surrounded by a plethora of other cells within the cellular fraction [14]. In order to isolate the CTCs from the blood sample, enrichment is required due to their low abundance. Several methods for CTC enrichment have been described in the past utilizing either biological properties of CTCs (in positive enrichment) such as marker expression or surrounding cells (depletion / negative enrichment) including immune cells. In addition to marker-based strategies, label-free methods based on physical properties have been established that allow the enrichment regardless of their marker expression for unbiased CTC detection. The enriched CTC fraction can be used for CTC enumeration but also for CTC molecular characterization as well as CTC cultivation for further insights into CTC biology [17, 19, 21]

For identification of CTCs, immunocytochemistry is often used to detect population-specific (e.g. EpCAM, cytokeratins, CD45), tissue- or tumor-specific or EMT-related antigen expression [17]. For a more extensive characterization, however, down-stream methods which allow for RNA or DNA analysis through e.g. RT-qPCR, RNAseq, whole genome amplification (WGA) and subsequent next generation sequencing (NGS) and/or proteomic analyses are needed to fully comprehend the state of the tumor. The detection of CTCs represents a highly specific blood-based technique that could be utilized for early detection strategies. However, as the number of CTCs is very low and enrichment procedures (negative, as well as positive enrichment) potentially lead to a loss of CTCs, the use of CTCs for early detection may lack sensitivity and negative predictive value. While positive enrichment methods based on cancer entities or primary tumor characteristics may provide a strong enrichment of CTCs, studies have also demonstrated a high degree of heterogeneity and discordance in primary tumor characteristics and detected CTCs. To increase the yield of CTCs, the use of larger blood volumes or diagnostic leukapheresis products (DLA) has been suggested. In metastatic breast cancer, an increase of almost 21-fold was observed by the authors comparing the CTC counts in peripheral blood with DLA products using the CellSearch platform. Strikingly, in two patients that had no detectable CTCs in the peripheral blood, CTCs were detected in the DLA products underlining the increase in sensitivity [22].

To further explore the functional properties of CTCs, suitable experimental models are needed. One good example for this is the establishment of in vitro CTC cell lines from the blood, even though being quite challenging. These model systems can be used to help understand the biology of CTCs, such as their heterogeneity in morphology, EMT status and features relevant for the development of metastasis [23]. Furthermore, more patient-relevant knowledge can be obtained, such as the (druggable) mutational status of both primary tumor and metastasis, evolutionary events, as well as potential drug sensitivities and resistances [23, 24].

In most studies, the average blood volume needed for CTC cell line establishment varies between 6 and 18 mL. Even though higher CTC counts from the same patient tend to have a higher success rate, which is often only the case in advanced stages, this property alone does not guarantee a successful establishment [23, 24]. For example, during the establishment of the first long-term stable CRC cell line, out of 71 patients only 2 patients (with 302 and 516 CTCs in their sample) gave rise to an CTC line ex vivo, of which one was only stable two months, whereas the latter was successfully established [25]. Nevertheless, Brungs et al. reported the establishment of a CTC cell line (UWG01CTC) from a distal oesophageal high grade neuroendocrine carcinoma patient with only 3 detectable CTCs (per 7.5 mL blood) [26]. In general, the success rates are relatively low, requiring several patient samples before successful establishment of a long-term stable CTC cell line [23, 27]. However, once established, CTC cell lines can serve as an excellent tool for drug screening applications and thus have the potential to become highly valuable in personalized medicine [27]. The use of DLA products can increase the yield and thereby the success rate of establishing an ex vivo CTC culture as described earlier by Mout et al. that reached a success rate of 35% for organoid expansion [28].

In contrast to commercially available, immortalized cell lines established from primary tumor tissue and metastatic sites, only a few CTC cell lines are available. In 2021, more than 300 successfully established CTC cell cultures have been reported, however, only less than 50 of these were stable for more than 6 months in culture [27]. Long-term stable CTC lines and also short-term cultivation of patient CTCs allow the analysis of viable cells and thereby pave the way towards a better understanding the biology of CTCs and identification of druggable targets.

The first permanent cell line derived from colon cancer CTCs (CTC-MCC-41) was successfully established by Cayrefourcq et al., which proved to harbor similar characteristics as the primary tumor [25]. The cell line was found to be highly sensitive towards AKT and mTOR inhibition, which suggests a possible benefit for the patient using targeted therapy approaches [29]. Moreover, in 2020, Koch et al. established a CTC cell line (CTC-ITB-01) from an ER+ breast cancer patient which showed high concordance between their primary CTCs. Furthermore, its CNA (copy number alteration) profile remains stable during culture. Of note, drug sensitivity testing of CTC-ITB-01 cells, also revealed a high susceptibility for CDK4/6 inhibitors, that was not administered to the patient who gave rise to the cell line and may represented a value treatment option [30]. Another noteworthy example of a long-term CTC cell line (> 2 years in culture) is the CTC-TJH-01 line, a non-small cell lung cancer CTC line, established by Que et al. [31]. The cell line exhibited an intermediate epithelial-mesenchymal phenotype, stem cell-like traits as well as an increased immune escape compared to established lung cancer cell lines including A549 [31]. Functionally, the authors demonstrated the tumorigenic and metastatic capacity in a murine xenotransplantation model in vivo after subcutaneous as well as intravenous (tail vein) injection. In line with the reported concordance of the primary tumor and CTCs in the CTC-ITB-01 cell line, the CTC-TJH-01 cell line shared wild type EGFR and a missense mutation at codon 12 of KRAS with the primary tumor [31].

These models thus prove to have a high prognostic value; however, their establishment remains challenging and is therefore only feasible in few selected patients. Using in vivo models, patient-derived xenografts (PDX) are furthermore suitable for the investigation of the potential to form metastases through injection of CTCs into immunodeficient mice. After intraductal injection of the CTC-ITB-01 cell line established by Koch et al., primary tumor growth was observed as well as spontaneous bone metastases, mirroring clinically relevant metastatic sites in ER+ breast cancer [30]. Consistently, Yu et al. reported the establishment of breast cancer CTC lines that retained ER positivity in 5 out of 6 lines. Moreover, in a murine subcutaneous xenotransplantation three CTC lines demonstrated tumorgenicity within 3 months with a matching molecular profile with regard to the respective primary tumor [32]. Similarly, the CTC-MCC-41 cell line as well as the corresponding primary tumor and xenografts harbor the same KRAS and BRAF mutations as well as CK20 expression [25]. The high capacity to retain the original molecular traits has also been confirmed in lung cancer, as demonstrated by CTC derived explants that were harvested after injection of CTCs into immunodeficient mice [33]. Faugeroux et al. established and characterized a prostate CTC-derived eXplant (CDX) model of model of neuroendocrine transdifferentiation in human castration resistant prostate cancer that allowed to study genetic and epigenetic mechanisms to further understand the biology of transdifferentiation and identify novel drug targets [34]. Overall, PDX models have shown metastasis formation in relevant organs and matching patient history which can be predictors of tumor development, ultimately representing a valuable tool in personalized medicine.

Circulating tumor cells in the clinical setting

The prognostic value of CTC detection has been extensively characterized in the past in different tumor entities. Detectable CTCs at the time of diagnosis are associated with reduced progression free and overall survival in many solid cancer entities [35–37]. In particular in breast cancer, there are numerous large-scale studies demonstrating a prognostic role of CTCs [38–41]. Similarly, for advanced/metastatic cancers or in relapse a negative prognosis has been already established in the past [42]. Although CTCs play a strong prognostic role in late stage cancers, the perspective of the use of CTC detection for early detection of cancer has been recently highlighted [43].

Molecular characterization of CTCs can also provide information on therapeutic targets. One example are the DETECT-III trials, the first randomized interventional study indicating clinical utility of CTC characterization that revealed that breast cancer patients with HER2 negative tumors have HER2 positive CTCs in the circulation. Strikingly, it has been demonstrated that these patients benefit from anti-HER2/anti-EGFR treatment using Lapatinib with regard to increased overall survival rates [44–47]. Although the reported CTC positivity rate of nearly two third [44] is consistent with other studies in metastatic breast cancer due to the EpCAM-based enrichment of the CellSearch system, EpCAMlow or EpCAM negative CTCs may be lost [48]. False-negative results for CTC positivity may be therefore reduced in the future by using additional CTC markers, label-free approaches, DLA products or in vivo capture systems [14, 49].

Despite the discordance of HER2 negative primary tumors and HER2 positive CTC reported in breast cancer, in lung cancer, a recent study analyzed the PD-L1 expression on CTCs, cytology imprints and tissue samples of NSCLC patients. The authors concluded that in clinical situations in which no tissue is available, the combination of cytological imprints and PD-L1 positive CTCs in the blood provides a predictive tool for tumoral PD-L1 status in NSCLC patients [50]. Moreover, a study on ALCAM expression in NSCLC patients with brain metastasis demonstrated that despite the high degree of heterogeneity of ALCAM expression on CTCs, a high concordance between ALCAM expression on CTCs and matched brain metastasis of the same patient was present [51].

For treatment monitoring, a meta-analysis also reported that in breast cancer patients CTC counts decrease after anti-tumor therapy and can therefore be used as an indicator of treatment response [52]. This may implicate the use of CTCs as a prognostic marker in the clinical routine or even implicate the ability to make use of the CTC counts as a real time marker for monitoring response rate while undergoing anti-tumor therapy.

Combination of liquid biopsy analytes

Due to the complementary nature of the different analytes found in the blood, numerous studies have demonstrated the great potential of combining CTC- and further liquid biomarker analyses for diagnostic and prognostic purpose [53]. However, the information obtained in these multiparameter studies greatly depends on the type of analyses being performed. Most studies use enumeration of CTCs which has been a marker for progression- and disease-free survival in singular studies of various cancer entities for over a decade and combined it with ctDNA detection which proved to enhance sensitivity and specificity [54–57].

On the other hand, analysis of genomic CTC DNA as a complementary analyte can give rise to a deeper understanding of the mutational state of the tumor cell and can thus provide insight into its spatial and temporal heterogeneity. Combined with ctDNA analysis, mutational profiling of both analytes was previously performed in several studies [58–60] and was found to reveal the same mutations in breast cancer patients [61, 62]. However, also mutations exclusively found in either one of the analytes were identified [61, 62]. Therefore, analysis of both sample types complements each other so that additional information can be obtained. Due to the diverse nature of analytes in the blood, the possibility of combining liquid analytes in not limited and thus, combined analysis of CTC with EVs (including their cargo), cell- free RNAs, circulating proteins, DNA methylation, platelets, as well as other cell types found in the circulation are all accounted in ongoing research and can add complimentary value [12, 63, 64].

A recent example of the combination of CTCs and tumor-derived EVs (tdEVs) has been published by Nanou et al. The authors examined the presence of tdEVs in both arms of the SWOG0500 trial (CTC response and non-response after the first treatment cycle). Nanou et al. demonstrated that the enumeration of tdEVs provides a strong prognostic marker complementary to the CTC response to further stratify patients into different risk groups [65].

Moreover, the feasibility of detecting more than two liquid analytes has already been successfully proven, however, pre-analytical parameters such as the choice of blood collection tube, and time to processing, among other factors, should be carefully taken into consideration [63, 66]. The combination of CTCs, ctDNA, EVs, proteins and metabolites is currently being assessed in the EU-funded PANCAID consortium [67] with the goal to detect pancreatic adenocarcinomas earlier than current imaging tools.

Standardization of liquid biopsy analysis and current clinical recommendations

Since the discovery of liquid biopsy as a tool for cancer diagnostics and prognostics over a decade ago [68], a multitude of isolation and analysis techniques have been developed. Furthermore, novel biomarkers such as CAFs, or CECs that can be found in the blood circulation are the topic of ongoing investigations and help to characterize the tumor (and its tumor microenvironment) more precisely, providing a deeper understanding on the state of the disease, and possible treatment options.

However, these advances also add a new level of complexity to clinical decision making. For a successful implementation into clinical practice, numerous pre-analytical and analytical factors must be taken into consideration [69]. Parameters such as sampling method and consumables, storage time, storage temperature, and moreover patient medication, time of sampling and comorbidities can all have an influence on the liquid analytes [66, 70]. Furthermore, a deep understanding of the correct choice of analyte and assay is urgently required to obtain and interpret the information suited for the respective patient and cancer entity. This multitude of parameters contributes to the lack of standardization and represents the biggest hurdle on the way to clinical implementation, when in fact, clinical practice needs guidelines and needs to be reliable and comparable.

To this day, numerous CTC detection methods are available and are used in research studies. Several efforts have been made to evaluate these methods to assess their technical validity and enhance their applicability in a clinical setting [71, 72]. Koch et al. demonstrated the necessity of studying pre-analytical and analytical parameters, and furthermore defining optimal conditions for CTC enrichment [70]. In a study by Lampignano et al. initiated by the CANCER-ID/ELBS consortium [73] different technologies for ctDNA purification, quantification, and characterization were evaluated in a multi-center study. Using spike-in experiments of TP53 mutated lung cancer cell line DNA in healthy donor blood, the study demonstrated the feasibility of mutation detection by NGS and ddPCR independent of the laboratory [74].

Despite these challenges, several liquid biopsy tests have already found their way into clinical practice.

The presence of CTCs has been shown to be a negative prognostic marker for overall survival and can be used to identify those patients at risk for relapse or progression [75]. Their clinical importance of CTC detection was acknowledged by the American Joint Committee’s (AJCC). Their breast cancer staging manual was updated in 2018 and includes the a new classification, cM0(i+), which is used to describe the presence of CTCs and or DTC clusters (≤ 0.2 mm) in the bone marrow or other organs distant from regional lymph nodes and the breast [76].

Moreover, the detection and genomic analysis of ctDNA has been proven to be a valuable tool in personalized medicine [77], especially with the recent advances in targeted therapy as well as immune checkpoint inhibition (ICI). The European Society for Medical Oncology (ESMO) therefore issued recommendations on the usage of ctDNA based assays for genotyping and treatment selection due to their high validity and clinical utility [78]. The detection of targetable mutations, e.g. EGFR in NSCLC or KRAS/NRAS/BRAF V600E in colorectal cancers, could lead to a faster diagnosis and treatment selection and could be taken into account when tissue biopsies are not available. Taken together, these recent advances have led to the implementation of several tests into the clinical routine including the analysis of targetable EGFR mutations and ALK rearrangements in NSCLC ctDNA [79], analysis of AR-V7 status in CTCs from mCRPC patients [80], and also multigene assays such as the NGS-based Guardant360 CDx [81]. Recent studies have also shown clinical utility of CTC enumeration and characterization for therapeutic decision making in metastatic breast cancer [82, 83].

However, the possibility of false-positive findings needs to be considered which might derive from clonal expansion of apoptotic hematopoietic cells in the blood (clonal hematopoiesis of indeterminate potential (CHIP)) [84]. False-negative results could furthermore occur when only low levels of plasma DNA are available, or the tumor does not shed sufficient DNA [78]. To address these challenges for the detection of MRD in colorectal, pancreatic and lung cancer the EU/IHI-funded GUIDE.MRD consortium was initiated in 2023 [85, 86].

Conclusions

In conclusion, there are still hurdles that need to be addressed before liquid biopsy tests will find their way into routine clinical practice. High costs for detection devices and personnel as well as their training, and the constant need for tumor surveillance due to its spatial and temporal heterogeneity are examples for the challenges that are faced today.

To overcome these obstacles, several international projects such as CANCER-ID (2015–2019), which was carried out under the umbrella of the European Union Innovative Medicines Initiative (IMI), have been established to standardize protocols for clinical validation of liquid biopsy methods. Apart from that, EU-wide as well as internationally active consortia and networks such as the European Liquid Biopsy Society (ELBS) provide a network of academic and industry partners which aim at closing the gap between the multitude of scientific publications and clinical implementation of liquid biopsy [87]. Moreover, international efforts are currently being made to update the RECIST criteria (Response Evaluation Criteria In Solid Tumors) by including ctDNA analysis for treatment response evaluation in solid tumors [88].

Despite the many challenges that still need to be overcome, the current advances in research and the joint efforts of academia and industry partners pave the way for the establishment of a successful clinical implementation of liquid biopsy. These endeavours will ultimately change cancer treatment through improvements in early detection, risk assessment and patient monitoring to prolong survival rates and enhance quality of life of many patients in the future.

Abbreviations

AJCC American Joint Committee

CAF Cancer-associated fibroblast

CDX CTC-derived eXplant

CEC Circulating endothelial cell

CHIP Clonal hematopoiesis of indeterminate potential

CNA Copy number alteration

CSC Cancer stem cell

CTC Circulating tumor cell

DTC Disseminated tumor cell

ELBS European Liquid Biopsy Society

EMT Epithelial–mesenchymal transition

EpCAM Epithelial cell adhesion molecule

EPISPOT Epithelial ImmunoSPOT

ER Estrogen receptor

ESMO European Society for Medical Oncology

EV Extracellular vesicle

FDA Food and Drug Administration

ICI Immune checkpoint inhibition

ILSA International Liquid Biopsy Standardization Alliance

IMI Innovative Medicines Initiative

NGS Next generation sequencing

NSCLC Non-small cell lung cancer

MET Mesenchymal-epithelial transition

PDX Patient-derived xenograft

RECIST Response Evaluation Criteria In Solid Tumors

tdEVs Tumor-derived EVs

WGA Whole genome amplification

Acknowledgements

The Figure was created using BioRender.com.

Author contributions

D.J.S. and S.S. reviewed the literature and wrote the original draft. All authors critically revised the original draft. All authors have read and agreed to the published version of the manuscript.

Funding

K.P. received grant/research support from EU/IHI GUIDE.MRD (No. 101112066), EU Horizon PANCAID (No. 101096309) and ERC Grant INJURMET (No. 834974).

Open Access funding enabled and organized by Projekt DEAL.

Declarations

Competing interests

K.P. received honoraria outside of this work from NRich, BMS, Agena, Menarini, Novartis, Sanofi, Illumina, Abcam, MSD, Eppendorf and Hummingbird.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Daniel J. Smit and Svenja Schneegans contributed equally to this work.
==== Refs
References

1. Fares J Molecular principles of metastasis: a hallmark of cancer revisited Signal Transduct Target Ther 2020 5 1 28 10.1038/s41392-020-0134-x 32296047
Fares J et al (2020) Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 5(1):2832296047 10.1038/s41392-020-0134-x
2. Massagué J Obenauf AC Metastatic colonization by circulating tumour cells Nature 2016 529 7586 298 306 10.1038/nature17038 26791720
Massagué J, Obenauf AC (2016) Metastatic colonization by circulating tumour cells. Nature 529(7586):298–30626791720 10.1038/nature17038
3. Thiery JP Epithelial-mesenchymal transitions in development and disease Cell 2009 139 5 871 890 10.1016/j.cell.2009.11.007 19945376
Thiery JP et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–89019945376 10.1016/j.cell.2009.11.007
4. Nieto MA EMT: 2016 Cell 2016 166 1 21 45 10.1016/j.cell.2016.06.028 27368099
Nieto MA et al (2016) EMT: 2016. Cell 166(1):21–4527368099 10.1016/j.cell.2016.06.028
5. Obenauf AC Massagué J Surviving at a Distance: Organ-Specific Metastasis Trends Cancer 2015 1 1 76 91 10.1016/j.trecan.2015.07.009 28741564
Obenauf AC, Massagué J (2015) Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer 1(1):76–9128741564 10.1016/j.trecan.2015.07.009
6. Werner S Heidrich I Pantel K Clinical management and biology of tumor dormancy in breast cancer Semin Cancer Biol 2022 78 49 62 10.1016/j.semcancer.2021.02.001 33582172
Werner S, Heidrich I, Pantel K (2022) Clinical management and biology of tumor dormancy in breast cancer. Semin Cancer Biol 78:49–6233582172 10.1016/j.semcancer.2021.02.001
7. Hofbauer LC Novel approaches to target the microenvironment of bone metastasis Nat Rev Clin Oncol 2021 18 8 488 505 10.1038/s41571-021-00499-9 33875860
Hofbauer LC et al (2021) Novel approaches to target the microenvironment of bone metastasis. Nat Rev Clin Oncol 18(8):488–50533875860 10.1038/s41571-021-00499-9
8. Braun S A pooled analysis of bone marrow micrometastasis in breast cancer N Engl J Med 2005 353 8 793 802 10.1056/NEJMoa050434 16120859
Braun S et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–80216120859 10.1056/NEJMoa050434
9. Hen O Barkan D Dormant disseminated tumor cells and cancer stem/progenitor-like cells: similarities and opportunities Sem Cancer Biol 2020 60 157 165 10.1016/j.semcancer.2019.09.002
Hen O, Barkan D (2020) Dormant disseminated tumor cells and cancer stem/progenitor-like cells: similarities and opportunities. Sem Cancer Biol 60:157–16510.1016/j.semcancer.2019.09.002
10. Dasgupta A Lim AR Ghajar CM Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol Oncol 2017 11 1 40 61 10.1002/1878-0261.12022 28085223
Dasgupta A, Lim AR, Ghajar CM (2017) Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol Oncol 11(1):40–6128085223 10.1002/1878-0261.12022
11. Pantel K Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells J Natl Cancer Inst 1993 85 17 1419 1424 10.1093/jnci/85.17.1419 7688814
Pantel K et al (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85(17):1419–14247688814 10.1093/jnci/85.17.1419
12. Lianidou E Pantel K Liquid biopsies Genes Chromosomes Cancer 2019 58 4 219 232 10.1002/gcc.22695 30382599
Lianidou E, Pantel K (2019) Liquid biopsies. Genes Chromosomes Cancer 58(4):219–23230382599 10.1002/gcc.22695
13. Joosse SA Pantel K Tumor-educated platelets as Liquid Biopsy in Cancer patients Cancer Cell 2015 28 5 552 554 10.1016/j.ccell.2015.10.007 26555171
Joosse SA, Pantel K (2015) Tumor-educated platelets as Liquid Biopsy in Cancer patients. Cancer Cell 28(5):552–55426555171 10.1016/j.ccell.2015.10.007
14. Keller L Pantel K Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells Nat Rev Cancer 2019 19 10 553 567 10.1038/s41568-019-0180-2 31455893
Keller L, Pantel K (2019) Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer 19(10):553–56731455893 10.1038/s41568-019-0180-2
15. Meng S Circulating tumor cells in patients with breast cancer dormancy Clin Cancer Res 2004 10 24 8152 8162 10.1158/1078-0432.CCR-04-1110 15623589
Meng S et al (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10(24):8152–816215623589 10.1158/1078-0432.CCR-04-1110
16. Barradas AM Terstappen LW Towards the Biological understanding of CTC: capture technologies, definitions and potential to create metastasis Cancers (Basel) 2013 5 4 1619 1642 10.3390/cancers5041619 24305653
Barradas AM, Terstappen LW (2013) Towards the Biological understanding of CTC: capture technologies, definitions and potential to create metastasis. Cancers (Basel) 5(4):1619–164224305653 10.3390/cancers5041619
17. Alix-Panabieres C Pantel K Liquid Biopsy: from Discovery to Clinical Application Cancer Discov 2021 11 4 858 873 10.1158/2159-8290.CD-20-1311 33811121
Alix-Panabieres C, Pantel K (2021) Liquid Biopsy: from Discovery to Clinical Application. Cancer Discov 11(4):858–87333811121 10.1158/2159-8290.CD-20-1311
18. Hyun KA Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer Oncotarget 2016 7 17 24677 24687 10.18632/oncotarget.8250 27013581
Hyun KA et al (2016) Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget 7(17):24677–2468727013581 10.18632/oncotarget.8250
19. Alix-Panabieres C EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients Recent Results Cancer Res 2012 195 69 76 10.1007/978-3-642-28160-0_6 22527495
Alix-Panabieres C (2012) EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res 195:69–7622527495 10.1007/978-3-642-28160-0_6
20. Pantel K Alix-Panabieres C Liquid biopsy and minimal residual disease - latest advances and implications for cure Nat Rev Clin Oncol 2019 16 7 409 424 10.1038/s41571-019-0187-3 30796368
Pantel K, Alix-Panabieres C (2019) Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol 16(7):409–42430796368 10.1038/s41571-019-0187-3
21. Eslami-S Z Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade Br J Cancer 2022 127 5 800 810 10.1038/s41416-022-01819-1 35484215
Eslami-S Z et al (2022) Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade. Br J Cancer 127(5):800–81035484215 10.1038/s41416-022-01819-1
22. Franken A Label-Free Enrichment and Molecular characterization of viable circulating tumor cells from Diagnostic Leukapheresis products Clin Chem 2019 65 4 549 558 10.1373/clinchem.2018.296814 30737205
Franken A et al (2019) Label-Free Enrichment and Molecular characterization of viable circulating tumor cells from Diagnostic Leukapheresis products. Clin Chem 65(4):549–55830737205 10.1373/clinchem.2018.296814
23. Shimada Y Cell lines of circulating Tumor cells: what is known and what needs to be resolved J Personalized Med 2022 12 5 666 10.3390/jpm12050666
Shimada Y et al (2022) Cell lines of circulating Tumor cells: what is known and what needs to be resolved. J Personalized Med 12(5):66610.3390/jpm12050666
24. Tayoun T CTC-derived models: a window into the seeding capacity of circulating tumor cells (CTCs) Cells 2019 8 10 1145 10.3390/cells8101145 31557946
Tayoun T et al (2019) CTC-derived models: a window into the seeding capacity of circulating tumor cells (CTCs). Cells 8(10):114531557946 10.3390/cells8101145
25. Cayrefourcq L Establishment and characterization of a cell line from human circulating colon cancer cells Cancer Res 2015 75 5 892 901 10.1158/0008-5472.CAN-14-2613 25592149
Cayrefourcq L et al (2015) Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 75(5):892–90125592149 10.1158/0008-5472.CAN-14-2613
26. Brungs D Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer Sci Rep 2020 10 1 539 10.1038/s41598-019-57164-6 31953491
Brungs D et al (2020) Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer. Sci Rep 10(1):53931953491 10.1038/s41598-019-57164-6
27. Smit DJ Pantel K Jücker M Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy Biochem Pharmacol 2021 188 114589 10.1016/j.bcp.2021.114589 33932470
Smit DJ, Pantel K, Jücker M (2021) Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy. Biochem Pharmacol 188:11458933932470 10.1016/j.bcp.2021.114589
28. Mout L Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells Eur J Cancer 2021 150 179 189 10.1016/j.ejca.2021.03.023 33932725
Mout L et al (2021) Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. Eur J Cancer 150:179–18933932725 10.1016/j.ejca.2021.03.023
29. Smit DJ et al (2020) High sensitivity of circulating Tumor cells derived from a colorectal Cancer patient for dual inhibition with AKT and mTOR inhibitors. Cells, 9(9)
30. Koch C Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity EMBO Mol Med 2020 12 9 e11908 10.15252/emmm.201911908 32667137
Koch C et al (2020) Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Mol Med 12(9):e1190832667137 10.15252/emmm.201911908
31. Que Z Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo Cancer Cell Int 2019 19 1 21 10.1186/s12935-019-0735-z 30718976
Que Z et al (2019) Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo. Cancer Cell Int 19(1):2130718976 10.1186/s12935-019-0735-z
32. Yu M Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility Science 2014 345 6193 216 220 10.1126/science.1253533 25013076
Yu M et al (2014) Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345(6193):216–22025013076 10.1126/science.1253533
33. Hodgkinson CL Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer Nat Med 2014 20 8 897 903 10.1038/nm.3600 24880617
Hodgkinson CL et al (2014) Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 20(8):897–90324880617 10.1038/nm.3600
34. Faugeroux V Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model Nat Commun 2020 11 1 1884 10.1038/s41467-020-15426-2 32313004
Faugeroux V et al (2020) Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model. Nat Commun 11(1):188432313004 10.1038/s41467-020-15426-2
35. Bidard FC Circulating Tumor cells in breast Cancer patients treated by Neoadjuvant Chemotherapy: a Meta-analysis J Natl Cancer Inst 2018 110 6 560 567 10.1093/jnci/djy018 29659933
Bidard FC et al (2018) Circulating Tumor cells in breast Cancer patients treated by Neoadjuvant Chemotherapy: a Meta-analysis. J Natl Cancer Inst 110(6):560–56729659933 10.1093/jnci/djy018
36. Effenberger KE Improved risk stratification by circulating Tumor Cell counts in Pancreatic Cancer Clin Cancer Res 2018 24 12 2844 2850 10.1158/1078-0432.CCR-18-0120 29559560
Effenberger KE et al (2018) Improved risk stratification by circulating Tumor Cell counts in Pancreatic Cancer. Clin Cancer Res 24(12):2844–285029559560 10.1158/1078-0432.CCR-18-0120
37. Reeh M Circulating Tumor cells as a biomarker for preoperative prognostic staging in patients with esophageal Cancer Ann Surg 2015 261 6 1124 1130 10.1097/SLA.0000000000001130 25607767
Reeh M et al (2015) Circulating Tumor cells as a biomarker for preoperative prognostic staging in patients with esophageal Cancer. Ann Surg 261(6):1124–113025607767 10.1097/SLA.0000000000001130
38. Rack B et al (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst, 106(5)
39. Riethdorf S Prognostic impact of circulating Tumor cells for breast Cancer patients treated in the Neoadjuvant Geparquattro Trial Clin Cancer Res 2017 23 18 5384 5393 10.1158/1078-0432.CCR-17-0255 28679772
Riethdorf S et al (2017) Prognostic impact of circulating Tumor cells for breast Cancer patients treated in the Neoadjuvant Geparquattro Trial. Clin Cancer Res 23(18):5384–539328679772 10.1158/1078-0432.CCR-17-0255
40. Trapp E Presence of circulating Tumor cells in high-risk early breast Cancer during Follow-Up and Prognosis J Natl Cancer Inst 2019 111 4 380 387 10.1093/jnci/djy152 30312434
Trapp E et al (2019) Presence of circulating Tumor cells in high-risk early breast Cancer during Follow-Up and Prognosis. J Natl Cancer Inst 111(4):380–38730312434 10.1093/jnci/djy152
41. Sparano J Association of circulating Tumor cells with late recurrence of Estrogen receptor–positive breast Cancer: a secondary analysis of a Randomized Clinical Trial JAMA Oncol 2018 4 12 1700 1706 10.1001/jamaoncol.2018.2574 30054636
Sparano J et al (2018) Association of circulating Tumor cells with late recurrence of Estrogen receptor–positive breast Cancer: a secondary analysis of a Randomized Clinical Trial. JAMA Oncol 4(12):1700–170630054636 10.1001/jamaoncol.2018.2574
42. Zhang L Meta-analysis of the prognostic value of circulating tumor cells in breast cancer Clin Cancer Res 2012 18 20 5701 5710 10.1158/1078-0432.CCR-12-1587 22908097
Zhang L et al (2012) Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 18(20):5701–571022908097 10.1158/1078-0432.CCR-12-1587
43. Lawrence R Circulating tumour cells for early detection of clinically relevant cancer Nat Reviews Clin Oncol 2023 20 7 487 500 10.1038/s41571-023-00781-y
Lawrence R et al (2023) Circulating tumour cells for early detection of clinically relevant cancer. Nat Reviews Clin Oncol 20(7):487–50010.1038/s41571-023-00781-y
44. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program < sup>☆ ESMO Open, 2021. 6(6)
45. Agelaki S Efficacy of Lapatinib in Therapy-resistant HER2-Positive circulating tumor cells in metastatic breast Cancer PLoS ONE 2015 10 6 e0123683 10.1371/journal.pone.0123683 26083256
Agelaki S et al (2015) Efficacy of Lapatinib in Therapy-resistant HER2-Positive circulating tumor cells in metastatic breast Cancer. PLoS ONE 10(6):e012368326083256 10.1371/journal.pone.0123683
46. Fehm T Abstract PD3-12: efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial Cancer Res 2021 81 4Supplement PD3 12
Fehm T et al (2021) Abstract PD3-12: efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial. Cancer Res 81(4Supplement):PD3–12
47. De Gregorio A Discordance in human epidermal growth factor receptor 2 (HER2) phenotype between primary tumor and circulating Tumor cells in women with HER2-Negative metastatic breast Cancer JCO Precis Oncol 2017 1 1 12 10.1200/PO.17.00023 35172510
De Gregorio A et al (2017) Discordance in human epidermal growth factor receptor 2 (HER2) phenotype between primary tumor and circulating Tumor cells in women with HER2-Negative metastatic breast Cancer. JCO Precis Oncol 1:1–1235172510 10.1200/PO.17.00023
48. Nicolazzo C EpCAM(low) circulating Tumor cells: gold in the Waste Dis Markers 2019 2019 p1718920 10.1155/2019/1718920
Nicolazzo C et al (2019) EpCAM(low) circulating Tumor cells: gold in the Waste. Dis Markers 2019:p171892010.1155/2019/1718920
49. Fehm TN Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting Cytometry A 2018 93 12 1213 1219 10.1002/cyto.a.23669 30551262
Fehm TN et al (2018) Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting. Cytometry A 93(12):1213–121930551262 10.1002/cyto.a.23669
50. Abdo M Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients Mol Oncol 2023 17 5 737 746 10.1002/1878-0261.13415 36892210
Abdo M et al (2023) Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients. Mol Oncol 17(5):737–74636892210 10.1002/1878-0261.13415
51. Münsterberg J ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium Neuro Oncol 2020 22 7 955 966 10.1093/neuonc/noaa028 32064501
Münsterberg J et al (2020) ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium. Neuro Oncol 22(7):955–96632064501 10.1093/neuonc/noaa028
52. Yan WT Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis Sci Rep 2017 7 43464 10.1038/srep43464 28337998
Yan WT et al (2017) Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis. Sci Rep 7:4346428337998 10.1038/srep43464
53. Keup C Kimmig R Kasimir-Bauer S Multimodality in liquid biopsy: does a combination uncover insights undetectable in individual blood analytes? J Lab Med 2022 46 4 255 264 10.1515/labmed-2022-0009
Keup C, Kimmig R, Kasimir-Bauer S (2022) Multimodality in liquid biopsy: does a combination uncover insights undetectable in individual blood analytes? J Lab Med 46(4):255–26410.1515/labmed-2022-0009
54. Fernandez-Garcia D Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer Breast Cancer Res 2019 21 1 1 13 10.1186/s13058-019-1235-8 30611295
Fernandez-Garcia D et al (2019) Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Res 21(1):1–1330611295 10.1186/s13058-019-1235-8
55. Davis AA Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer Breast Cancer Res 2019 21 1 1 8 10.1186/s13058-019-1229-6 30611295
Davis AA et al (2019) Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. Breast Cancer Res 21(1):1–830611295 10.1186/s13058-019-1229-6
56. Rossi G Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer Clin Cancer Res 2018 24 3 560 568 10.1158/1078-0432.CCR-17-2092 29180605
Rossi G et al (2018) Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer. Clin Cancer Res 24(3):560–56829180605 10.1158/1078-0432.CCR-17-2092
57. Wang W Plasma cell-free DNA integrity plus circulating tumor cells: a potential biomarker of no distant metastasis breast cancer Neoplasma 2017 64 4 611 618 10.4149/neo_2017_417 28485169
Wang W et al (2017) Plasma cell-free DNA integrity plus circulating tumor cells: a potential biomarker of no distant metastasis breast cancer. Neoplasma 64(4):611–61828485169 10.4149/neo_2017_417
58. Liu HE et al (2020) Detection of EGFR mutations in cfDNA and CTCs, and comparison to Tumor tissue in Non-small-cell-lung-cancer (NSCLC) patients. Frontiers in Oncology, p 10
59. Welter L Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient Mol Case Stud 2020 6 6 a005819 10.1101/mcs.a005819
Welter L et al (2020) Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. Mol Case Stud 6(6):a00581910.1101/mcs.a005819
60. Shishido SN Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib npj Breast Cancer 2022 8 1 22 10.1038/s41523-022-00390-5 35181666
Shishido SN et al (2022) Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib. npj Breast Cancer 8(1):2235181666 10.1038/s41523-022-00390-5
61. Keup C Multimodal targeted deep sequencing of circulating Tumor cells and matched cell-free DNA provides a more Comprehensive Tool to identify therapeutic targets in metastatic breast Cancer patients Cancers 2020 12 5 1084 10.3390/cancers12051084 32349306
Keup C et al (2020) Multimodal targeted deep sequencing of circulating Tumor cells and matched cell-free DNA provides a more Comprehensive Tool to identify therapeutic targets in metastatic breast Cancer patients. Cancers 12(5):108432349306 10.3390/cancers12051084
62. Tzanikou E PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study Mol Oncol 2019 13 12 2515 2530 10.1002/1878-0261.12540 31254443
Tzanikou E et al (2019) PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. Mol Oncol 13(12):2515–253031254443 10.1002/1878-0261.12540
63. Keup C Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer Genome Med 2021 13 1 1 14 10.1186/s13073-021-00902-1 33397400
Keup C et al (2021) Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer. Genome Med 13(1):1–1433397400 10.1186/s13073-021-00902-1
64. Buscail E High clinical value of Liquid Biopsy to detect circulating Tumor cells and Tumor exosomes in Pancreatic Ductal Adenocarcinoma patients Eligible for Up-Front surgery Cancers 2019 11 11 1656 10.3390/cancers11111656 31717747
Buscail E et al (2019) High clinical value of Liquid Biopsy to detect circulating Tumor cells and Tumor exosomes in Pancreatic Ductal Adenocarcinoma patients Eligible for Up-Front surgery. Cancers 11(11):165631717747 10.3390/cancers11111656
65. Nanou A et al Tumor-derived extracellular vesicles as complementary prognostic factors to circulating Tumor cells in metastatic breast Cancer. JCO Precision Oncology, 2023(7): p. e2200372
66. Schneegans S Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients Mol Oncol 2020 14 5 1001 1015 10.1002/1878-0261.12669 32246814
Schneegans S et al (2020) Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. Mol Oncol 14(5):1001–101532246814 10.1002/1878-0261.12669
67. PANCAID Consortium. PANcreatic CAncer Initial Detection via liquid biopsy (PANCAID) (2023) [Accessed : 21 August 2023]; Available from: https://pancaid-project.eu
68. Pantel K Alix-Panabieres C Circulating tumour cells in cancer patients: challenges and perspectives Trends Mol Med 2010 16 9 398 406 10.1016/j.molmed.2010.07.001 20667783
Pantel K, Alix-Panabieres C (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16(9):398–40620667783 10.1016/j.molmed.2010.07.001
69. Roeper CM et al (2023) „Liquid biopsy –schon reif für Therapieentscheidungen? best practice onkologie, : p. 1–9
70. Koch C et al (2020) Pre-analytical and Analytical variables of label-independent Enrichment and Automated Detection of circulating Tumor cells in Cancer patients. Cancers (Basel), 12(2)
71. Neves RPL Proficiency testing to assess Technical Performance for CTC-Processing and Detection methods in CANCER-ID Clin Chem 2021 67 4 631 641 10.1093/clinchem/hvaa322 33491069
Neves RPL et al (2021) Proficiency testing to assess Technical Performance for CTC-Processing and Detection methods in CANCER-ID. Clin Chem 67(4):631–64133491069 10.1093/clinchem/hvaa322
72. Maertens Y Comparison of isolation platforms for detection of circulating renal cell carcinoma cells Oncotarget 2017 8 50 87710 87717 10.18632/oncotarget.21197 29152114
Maertens Y et al (2017) Comparison of isolation platforms for detection of circulating renal cell carcinoma cells. Oncotarget 8(50):87710–8771729152114 10.18632/oncotarget.21197
73. European Liquid Biopsy Society. European Liquid Biopsy Society (ELBS) (2023) [Accessed : 21 August 2023]; Available from: www.elbs.eu
74. Lampignano R Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre)analytical work flows Clin Chem 2020 66 1 149 160 10.1373/clinchem.2019.306837 31628139
Lampignano R et al (2020) Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre)analytical work flows. Clin Chem 66(1):149–16031628139 10.1373/clinchem.2019.306837
75. Heidrich I Liquid biopsies: potential and challenges Int J Cancer 2021 148 3 528 545 10.1002/ijc.33217 32683679
Heidrich I et al (2021) Liquid biopsies: potential and challenges. Int J Cancer 148(3):528–54532683679 10.1002/ijc.33217
76. Amin MB The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging CA Cancer J Clin 2017 67 2 93 99 10.3322/caac.21388 28094848
Amin MB et al (2017) The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin 67(2):93–9928094848 10.3322/caac.21388
77. Bardelli A Pantel K Liquid biopsies, what we do not know (yet) Cancer Cell 2017 31 2 172 179 10.1016/j.ccell.2017.01.002 28196593
Bardelli A, Pantel K (2017) Liquid biopsies, what we do not know (yet). Cancer Cell 31(2):172–17928196593 10.1016/j.ccell.2017.01.002
78. Pascual J ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group Ann Oncol 2022 33 8 750 768 10.1016/j.annonc.2022.05.520 35809752
Pascual J et al (2022) ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol 33(8):750–76835809752 10.1016/j.annonc.2022.05.520
79. Hofman P Implementation of the clinical practice of liquid biopsies for thoracic oncology the experience of the RespirERA university hospital institute (Nice, France) J Liquid Biopsy 2023 1 100004 10.1016/j.jlb.2023.100004
Hofman P (2023) Implementation of the clinical practice of liquid biopsies for thoracic oncology the experience of the RespirERA university hospital institute (Nice, France). J Liquid Biopsy 1:10000410.1016/j.jlb.2023.100004
80. Rao A Antonarakis ES Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility? Ann Transl Med 2019 7 Suppl 8 S354 10.21037/atm.2019.09.92 32016072
Rao A, Antonarakis ES (2019) Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility? Ann Transl Med 7(Suppl 8):S35432016072 10.21037/atm.2019.09.92
81. Ignatiadis M Sledge GW Jeffrey SS Liquid biopsy enters the clinic — implementation issues and future challenges Nat Reviews Clin Oncol 2021 18 5 297 312 10.1038/s41571-020-00457-x
Ignatiadis M, Sledge GW, Jeffrey SS (2021) Liquid biopsy enters the clinic — implementation issues and future challenges. Nat Reviews Clin Oncol 18(5):297–31210.1038/s41571-020-00457-x
82. Bidard F-C et al (2023) Overall survival with circulating Tumor Cell Count–Driven choice of therapy in advanced breast Cancer: a Randomized Trial. J Clin Oncol, : p. JCO.23.00456.
83. Fehm T Efficacy of Lapatinib in patients with HER2-Negative metastatic breast Cancer and HER2-Positive circulating tumor cells—the DETECT III Clinical Trial Clin Chem 2024 70 1 307 318 10.1093/clinchem/hvad144 38175595
Fehm T et al (2024) Efficacy of Lapatinib in patients with HER2-Negative metastatic breast Cancer and HER2-Positive circulating tumor cells—the DETECT III Clinical Trial. Clin Chem 70(1):307–31838175595 10.1093/clinchem/hvad144
84. Lui YY Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation Clin Chem 2002 48 3 421 427 10.1093/clinchem/48.3.421 11861434
Lui YY et al (2002) Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 48(3):421–42711861434 10.1093/clinchem/48.3.421
85. GUIDE.MRD Consortium. Guiding multi-modal therapies against MRD by liquid biopsies (2023) [Accessed : 21 August 2023]; Available from: https://www.guidemrd-horizon.eu
86. Pantel K 237TiP GUIDE.MRD: a Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to improve patient outcomes Ann Oncol 2023 34 S276 S277 10.1016/j.annonc.2023.09.2960
Pantel K et al (2023) 237TiP GUIDE.MRD: a Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to improve patient outcomes. Ann Oncol 34:S276–S27710.1016/j.annonc.2023.09.2960
87. Connors D International liquid biopsy standardization alliance white paper Crit Rev Oncol Hematol 2020 156 103112 10.1016/j.critrevonc.2020.103112 33035734
Connors D et al (2020) International liquid biopsy standardization alliance white paper. Crit Rev Oncol Hematol 156:10311233035734 10.1016/j.critrevonc.2020.103112
88. Jakobsen AKM Spindler KG ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology Eur J Cancer 2023 180 180 183 10.1016/j.ejca.2022.11.039 36610263
Jakobsen AKM, Spindler KG (2023) ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology. Eur J Cancer 180:180–18336610263 10.1016/j.ejca.2022.11.039
